ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stageEarly clinical data are expected in second half of ...

Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral vector-based gene therapy ? ET3 ? for hemophilia A at the Annual Meeting of the American ...

To develop the next generation of in vivo T cell therapy, Novartis will leverage Vyriad's active targeting lentiviral vector platform to discover and develop new in vivo CAR-T cell therapy candidates.

Vyriad's targeted lentiviral vector platform provides T ... Inc. Vyriad is a clinical-stage biotechnology company developing the next generation of targeted genetic therapies using engineered ...

Infosys (NSE: INFY) (BSE: INFY) , a global leader in next-generation digital services and consulting, today announced a strategic collaboration with Kardex, a leading global provider of intralogistics ...

Lentiviral transduction of producer cells ... had 3.7-fold improved potency and was designated as the fifth generation (v5) BE-eVLPs. The potencies of v4 and v5 BE-eVLPs were compared, which ...

Phase 1 study and Investigator Initiated Trial evaluating KL003 for patients with beta thalassemia demonstrated an encouraging efficacy signal ...

“As part of our regular portfolio assessment, we have made the strategic decision to deprioritize ex vivo lentiviral-based ... but the earlier-generation technology has its share of problems ...